T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy

Authors:
Open Access
Publisher website
Google Scholar
Abstract
A key phenomenon in cancer is the establishment of a highly immunosuppressive tumour microenvironment (TME). Despite advances in immunotherapy, where the purpose is to induce tumour recognition and hence hereof tumour eradication, the majority of patients applicable for such treatment still fail to respond. It has been suggested that high immunological activity in the tumour is essential for achieving effective response to immunotherapy, which therefore have led to exploration of strategies that triggers inflammatory pathways. Here activation of the stimulator of interferon genes (STING) signalling pathway has been considered an attractive target, as it is a potent trigger of pro‐inflammatory cytokines and types I and III interferons. However, immunotherapy combined with targeted STING agonists has not yielded sustained clinical remission in humans. This suggests a need for exploring novel adjuvants to improve the innate immunological efficacy. Here, we demonstrate that extracellular vesicles (EVs), derived from activated CD4+ T cells (T‐EVs), sensitizes macrophages to elevate STING activation, mediated by IFNγ carried on the T‐EVs. Our work support that T‐EVs can disrupt the immune suppressive environment in the tumour by reprogramming macrophages to a pro‐inflammatory phenotype, and priming them for a robust immune response towards STING activation.
All Related Versions
Funding Information
  • Danmarks Frie Forskningsfond (8026‐00018B)
  • Kræftens Bekæmpelse (R149‐A10167‐16‐S47, R167‐A10737‐17‐S2, R246‐A14695)
  • Lundbeck Foundation (R238‐2016‐2708)
  • Gilead Foundation (Gilead Nordic Fellowship Programme 705 07591)
  • Novo Nordisk Fonden (NNF20OC0062825)

This publication has 61 references indexed in Scilit: